Journal
BRAIN AND BEHAVIOR
Volume 10, Issue 7, Pages -Publisher
WILEY
DOI: 10.1002/brb3.1672
Keywords
Alzheimer's disease; amyloid-beta; ELISA; receptor-associated protein; tau
Categories
Funding
- National Health and Medical Research Council of Australia [1079679, 1095127, 605530]
- Rebecca Cooper Foundation
Ask authors/readers for more resources
Introduction One of the major neuropathological features of Alzheimer's disease (AD) is the accumulation of amyloid-beta (A beta) protein in the brain. Evidence suggests that the low-density lipoprotein receptor-associated protein (RAP) binds strongly to A beta and enhances its cellular uptake and that decreased RAP expression correlates with increased A beta production in animal models of AD. Methods The current study examined whether RAP levels change in AD human brain tissue and whether they are related to the amount of AD pathology. RAP and NeuN levels were determined by Western blot, while low-density lipoprotein receptor-related protein 1 (LRP1), tau and A beta levels were determined by ELISA in the temporal cortex of 17 AD and 16 control cases. Results An increase in total A beta and insoluble and soluble tau protein was observed in AD brain tissue. In contrast, RAP levels were significantly decreased in AD brain tissue compared to controls. Correlation analysis revealed that levels of RAP correlated with both total A beta and soluble and insoluble tau levels. Neither LRP1 nor NeuN levels were significantly altered in AD brain tissue homogenates and did not correlate with A beta or tau protein levels. Conclusion Reduction in RAP may contribute to the accumulation and aggregation of A beta in the AD brain.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available